share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

SEC announcement ·  Mar 13 08:49
Summary by Futu AI
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.